ALN-4324 (GRB14) Overview

An Investigational RNAi Therapeutic

Disease State(s) Under Investigation	Type 2 diabetes mellitus[1]
MoA	Designed to target production of growth factor receptor-bound protein (GRB14) in the liver[2]
Route of Administration	Subcutaneous[3]

Clinical Trials Overview

Phase 1	Treatment Arms	Primary Endpoint
Active Safety and Tolerability of Single Ascending Doses of **ALN-4324** Healthy Volunteers[3]	ALN-4324; placebo	Safety (frequency of AEs up to 9 months)

Phase 2	Treatment Arms	Primary Endpoint
Active Safety, Tolerability, Efficacy, PK, and PD of Multiple Doses of **ALN-4324** Adult overweight to obese patients with T2DM[3]	ALN-4324; placebo	Safety (frequency of AEs up to 12 months)
Active Effect of **ALN-4324** on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Adult overweight to obese patients with T2DM[4]	ALN-4324; placebo	Change from Baseline in M-value

AE, adverse event; GRB14, growth factor receptor-bound protein 14; M-value, glucose infusion rate at steady state; MoA, mechanism of action; PD, pharmacodynamics; PK, pharmacokinetics; RNA, ribonucleic acid; RNAi, RNA interference; T2DM, type 2 diabetes mellitus. 1. Alnylam Pharmaceuticals, Inc. 2025. https://investors.alnylam.com/press-release?id=28716 (Accessed May 4, 2026). 2. Jadhav V. Presented at Alnylam R&D Day, February 25, 2025. 3. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT06845202 (Accessed May 4, 2026). 4. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT07465224 (Accessed August 7, 2026).

Alnylam